These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 23082308)
21. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Neumiller JJ; Campbell RK Ann Pharmacother; 2009 Sep; 43(9):1433-44. PubMed ID: 19638470 [TBL] [Abstract][Full Text] [Related]
22. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy. Kumar A Expert Opin Biol Ther; 2014 Jun; 14(6):869-78. PubMed ID: 24702171 [TBL] [Abstract][Full Text] [Related]
23. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Garber AJ Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667 [TBL] [Abstract][Full Text] [Related]
24. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Thompson AM; Trujillo JM Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404 [TBL] [Abstract][Full Text] [Related]
25. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Mikhail N Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986 [TBL] [Abstract][Full Text] [Related]
26. Next-generation GLP-1 therapy: an introduction to liraglutide. Repas T Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Bode BW; Brett J; Falahati A; Pratley RE Am J Geriatr Pharmacother; 2011 Dec; 9(6):423-33. PubMed ID: 22055210 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Nauck M; Frid A; Hermansen K; Shah NS; Tankova T; Mitha IH; Zdravkovic M; Düring M; Matthews DR; Diabetes Care; 2009 Jan; 32(1):84-90. PubMed ID: 18931095 [TBL] [Abstract][Full Text] [Related]
31. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Davies M; Speight J Diabetes Obes Metab; 2012 Oct; 14(10):882-92. PubMed ID: 22420869 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori RE; Lau J; Pittas AG JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. Kesavadev J; Shankar A; Gopalakrishnan G; Jothydev S Diabetes Metab Syndr; 2015; 9(1):30-3. PubMed ID: 25605673 [TBL] [Abstract][Full Text] [Related]
34. Liraglutide for type 2 diabetes mellitus. Kela R; Khunti K; Davies MJ Expert Opin Biol Ther; 2011 Jul; 11(7):951-9. PubMed ID: 21563859 [TBL] [Abstract][Full Text] [Related]
35. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M; Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856 [TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Nauck M; Frid A; Hermansen K; Thomsen AB; During M; Shah N; Tankova T; Mitha I; Matthews DR Diabetes Obes Metab; 2013 Mar; 15(3):204-12. PubMed ID: 22985213 [TBL] [Abstract][Full Text] [Related]
37. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Siddiqui NI Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763 [TBL] [Abstract][Full Text] [Related]
38. Liraglutide: a new treatment for type 2 diabetes. Vilsboll T Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Li CJ; Li J; Zhang QM; Lv L; Chen R; Lv CF; Yu P; Yu DM Cardiovasc Diabetol; 2012 Nov; 11():142. PubMed ID: 23153177 [TBL] [Abstract][Full Text] [Related]
40. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Katout M; Zhu H; Rutsky J; Shah P; Brook RD; Zhong J; Rajagopalan S Am J Hypertens; 2014 Jan; 27(1):130-9. PubMed ID: 24263424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]